Kathleen Lambert, MD
Hematology & Oncology · Conyers, GANPI 1689651390
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,938 of the $52,422 with a category attached, or 76.2%. Johnson & Johnson accounts for 91.6% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2023 at $17,093 and has fallen 69.8% since, to $5,159 in 2025.
Across 169 payments — averaging $310.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$48K
- Amgen$2K
- Novartis$276
- AbbVie$182
- Daiichi Sankyo Inc.$179
- AstraZeneca$177
- plus $2K from 39 others
Across 3 payments — averaging $12,561 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$37K
- Merck$542
What the payments were for
- Consulting fees$7,78515%
- Speaking & faculty fees$39,93876%
- Travel & lodging$8642%
- Food & beverage$3,7947%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,422 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 40 | $640,397 |
| PomalystPomalidomide | 21 | $433,447 |
| RevlimidLenalidomide | 21 | $357,057 |
| KisqaliRibociclib Succinate | 18 | $289,078 |
| TagrissoOsimertinib Mesylate | 13 | $207,426 |
| CalquenceAcalabrutinib Maleate | 12 | $169,399 |
| TavalisseFostamatinib Disodium | 12 | $130,962 |
| EliquisApixaban | 118 | $101,856 |
| XareltoRivaroxaban | 31 | $33,851 |
| Oxycodone Hcl | 75 | $4,347 |
| Exemestane | 22 | $3,178 |
| Anagrelide Hcl | 20 | $2,755 |
| Imatinib Mesylate | 20 | $1,685 |
| Gabapentin | 97 | $1,652 |
| Tenofovir Disoproxil Fumarate | 11 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25 | $640,39740 claims |
| AstraZenecaTagrisso, Calquence | $177 | $376,82525 claims |
| Bristol Myers SquibbRevlimid | $106 | $357,05721 claims |
| NovartisKisqali | $276 | $289,07818 claims |
| Rigel Pharmaceuticals, Inc.Tavalisse | $20 | $130,96212 claims |
| PfizerEliquis | $74 | $101,856118 claims |
| Johnson & JohnsonXarelto | $48,023 | $33,85131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Conyers
- Chandar BhimaniConyers$483K
- Priya RudolphAthens$745K
- Aron KefelaHiram$591K
- Ticiana LealAtlanta$450K
- Steven McCuneMarietta$450K
- Jorge LeguizamoLawrenceville$409K
- Trevor FeinsteinFayetteville$341K
- Jigarkumar ParikhAugusta$267K
- Ajay NookaAtlanta$222K
- Abdullah KutlarAugusta$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.